Curis Inc.
| NASDAQ: CRIS | Healthcare / Biotechnology / USA |
| 11.37 | +0.5500 | +5.08% | Vol 1.77M | 1Y Perf 1 594.03% |
| Apr 13th, 2021 16:00 DELAYED |
| BID | 11.21 | ASK | 11.49 | ||
| Open | 10.49 | Previous Close | 10.82 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 13.75 | Analyst Rating | — 0.00 | |
| Potential % | 20.93 | Finscreener Ranking | ★★★★+ — 55.62 | |
| Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★★ — 57.09 | |
| Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★+ 56.29 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
| Market Cap | 1.04B | Earnings Rating | Buy | |
| Price Range Ratio 52W % | 83.78 | Earnings Date | 11th May 2021 |
Today's Price Range 10.4111.50 | 52W Range 0.680013.44 | 5 Year PE Ratio Range -2.50-2.90 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | -7.68% | ||
| 1 Month | -0.92% | ||
| 3 Months | 2.66% | ||
| 6 Months | 751.97% | ||
| 1 Year | 1 594.03% | ||
| 3 Years | 254.75% | ||
| 5 Years | 22.95% | ||
| 10 Years | -43.05% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -189.24 | |||
ROE last 12 Months | -63.80 | |||
ROA (5Y Avg) | -36.92 | |||
ROA last 12 Months | -24.66 | |||
ROC (5Y Avg) | -73.79 | |||
ROC last 12 Months | -10.67 | |||
Return on invested Capital Q | -10.67 | |||
Return on invested Capital Y | -45.25 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 2.40 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -18.20 | ||||
| 8.28 | ||||
| 129.52 | ||||
| 36.40 | ||||
| -63.10 | ||||
| -0.53 | ||||
| 8.90 | ||||
| 1.43 | ||||
| 921.70M | ||||
| Forward PE | -26.74 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 17.00 | ||||
| 17.10 | ||||
| 0.04 | ||||
| 0.06 | ||||
| -4.90 | ||||
| Leverage Ratio | 2.60 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 95.00 | ||||
| -229.00 | ||||
| -227.70 | ||||
| -450.20 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 8.13M | ||||
| 0.09 | ||||
| 1.30 | ||||
| 7.27 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.07 | -0.11 | -57.14 |
| Q03 2020 | - | -0.11 | - |
| Q02 2020 | - | -0.17 | - |
| Q01 2020 | - | -0.28 | - |
| Q04 2019 | - | -0.26 | - |
| Q03 2019 | - | -0.19 | - |
| Q02 2019 | - | -0.22 | - |
| Q01 2019 | - | -0.19 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.09 | 18.18 | Positive |
| 6/2021 QR | -0.09 | 18.18 | Positive |
| 12/2021 FY | -0.41 | 6.82 | Positive |
| 12/2022 FY | -0.43 | 20.37 | Positive |
| Next Report Date | 11th May 2021 |
| Estimated EPS Next Report | -0.09 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.77M |
| Shares Outstanding | 91.52M |
| Trades Count | 14.28K |
| Dollar Volume | 11.27M |
| Avg. Volume | 2.08M |
| Avg. Weekly Volume | 1.24M |
| Avg. Monthly Volume | 2.39M |
| Avg. Quarterly Volume | 2.02M |
Curis Inc. (NASDAQ: CRIS) stock closed at 10.82 per share at the end of the most recent trading day (a -5.91% change compared to the prior day closing price) with a volume of 1.75M shares and market capitalization of 1.04B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 28 people. Curis Inc. CEO is James E. Dentzer.
The one-year performance of Curis Inc. stock is 1594.03%, while year-to-date (YTD) performance is 32.11%. CRIS stock has a five-year performance of 22.95%. Its 52-week range is between 0.68 and 13.44, which gives CRIS stock a 52-week price range ratio of 83.78%
Curis Inc. currently has a PE ratio of -18.20, a price-to-book (PB) ratio of 8.28, a price-to-sale (PS) ratio of 129.52, a price to cashflow ratio of 36.40, a PEG ratio of 2.32, a ROA of -24.66%, a ROC of -10.67% and a ROE of -63.80%. The company’s profit margin is -%, its EBITDA margin is -227.70%, and its revenue ttm is $8.13 Million , which makes it $0.09 revenue per share.
Of the last four earnings reports from Curis Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.09 for the next earnings report. Curis Inc.’s next earnings report date is 11th May 2021.
The consensus rating of Wall Street analysts for Curis Inc. is — (0), with a target price of $13.75, which is +20.93% compared to the current price. The earnings rating for Curis Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Curis Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Curis Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.90, ATR14 : 0.93, CCI20 : -99.34, Chaikin Money Flow : 0.16, MACD : -0.03, Money Flow Index : 60.59, ROC : 4.95, RSI : 43.02, STOCH (14,3) : 25.79, STOCH RSI : 0.22, UO : 52.69, Williams %R : -74.21), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Curis Inc. in the last 12-months were: James E. Dentzer (Sold 5 377 shares of value $57 780 )
Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
CEO: James E. Dentzer
Telephone: +1 617 503-6500
Address: 4 Maguire Road, Lexington 02421, MA, US
Number of employees: 28
